Are Future Health Care Workers Protected Against Hepatitis B Vaccination Coverage and Seroprotection Among Healthcare Students at an Academic Institution in the United States, 2000 – 2010

Introduction

- The Centers for Disease Control and Prevention (CDC) and the Advisory Committee for Immunization Practices (ACIP) Hepatitis B vaccination recommendations:
- 1982: Hepatitis B vaccination recommended for health care workers
- 1990's: Post-vaccination antibody to hepatitis B surface antigen [anti-HBs] testing recommended for health care workers
- 1995: Routine vaccination of unvaccinated children aged 11-12 years
- 1999: Routine vaccination of unvaccinated children aged < 18 years
- Healthy People 2010 goal of achieving 90% hepatitis B vaccination coverage among health care workers set as a benchmark for the elimination of occupationally acquired hepatitis B infection in the United States.
- 8% of needle stick injuries among medical students involve a known hepatitis B
- Little or no information is available regarding hepatitis B vaccination coverage among health care students in the United States.

Objectives

- Estimate coverage and documentation of Hepatitis B vaccination
- Assess documentation of anti-HBs concentration
- Estimate seroprotection rates (anti-HBs concentration \geq 10 mlU/mL) and determine factors associated with seroprotection
- Evaluate implementation of the 1995 and 1999 ACIP recommendations

In a cohort of medical, nursing, and allied health students (health care students) upon enrollment at an academic institution in the United States.

Methods

- Target Population
- Matriculating health care students between January 2000 and January 2010 at a university in the southeastern United States

Data Source

– Hepatitis B immunization electronic records

Statistical Analysis

- Continuous data were reported as median along with the range.
- Categorical data were reported as percentages.
- Fisher's exact test was performed to determine factors associated with anti-HBs≥10 mIU/mL.
- A p-value < 0.05 was considered statistically significant.

E-mail: cdcinfo@cdc.gov Web: www.cdc.gov The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Rania A. Tohme MD, MPH,^{1,2} Bruce Ribner, MD,MPH,³ Michael J. Huey, MD,³ Philip R. Spradling, MD² ¹Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA ²Division of Viral Hepatitis, CDC, Atlanta, GA ³Emory University, Atlanta, GA





Table 1. Age at vaccination and seroprotection characteristics of health care students, by number of recorded lifetime doses of hepatitis B vaccine received

cerveu				
	Total number of documented vaccine doses in the student database			
	< 3 doses	3 doses	>3 doses	
	N= 1634	N= 2168	N=267	
ge at primary hepatitis B vaccination series, ears				
Dose 1, median age (range)	23.5ª	22.0	19.4	
	(3.4 –56.6)	(0 – 59.6)	(0 – 56.4)	
Dose 2, median age (range)	24.1 ^ь	22.2	20.3	
	(7.1– 47.9)	(0.08 – 59.7)	(0.5 – 56.5)	
Dose 3, median age (range)	-	22.9 (0.5– 60.1)	21.5 (2.0– 56.9)	
udents with available anti-HBs concentration	1489/1634	1918/2168	181/267	
ost primary series vaccination, n (%)	(91.1%)	(88.5%)	(67.8%)	
ge at post-vaccine anti-HBs concentration,	24.0	24.0	23.9	
ears median (range)	(8.8– 62.9)	(14.1–60.2)	(18.7– 60.3)	
terval between primary series and first anti-	8.4	7.6	42.0	
Bs concentration, months median (range)	(0.5 – 172.8)	(0.06 – 256.8)	(1.2 – 172.8)	
ost-primary series anti-HBs concentration ≥10	1382/1489	1898/1918	20/181	
IU/mL, n (%)°	(92.8%)	(98.9%)	(11.0%)	
^a n=469 students; ^b n= 186 students; ^c Among students with available anti-HBs concentration before administration of booster dose(s).				

	Anti HBs concentration after primary vaccine series				
	<10 mIU/mL		≥ 10 mIU/mL		
	n	%	n	%	P-value ^a
Total	181	8.6	1918	91.4	
Interval between primary series and anti-HBs					<0.001
< 5 years	117	7.2	1499	92.8	
5 to < 10 years	51	12.8	346	87.2	
10 to < 15 years	13	16.5	66	83.5	
\geq 15 years	0	0.0	7	100.0	
Age at primary vaccine series					0.2
<1 years	0	0.0	6	100.0	
1 to <5 years	0	0.0	1	100.0	
5 to <11 years	5	26.3	14	73.7	
11 to <20 years	73	12.9	494	87.1	
20 to < 30 years	75	6.0	1178	94.0	
30 to < 40 years	23	11.7	173	88.3	
\geq 40years	5	8.8	52	91.2	
^a Fisher's exact test					

No.	No.	No. students with	Anti-HBs ≥ 10ml
booster	students ¹	anti-HBs results after	n (%) ³
doses		each booster dose ²	(///
1	184	100	95 (6
2	32	19	17 (*
3	39	28	20 (*
≥4	3	3	3
Total	258	150	135 (9

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Viral Hepatitis





